

Commissioner of Patents  
USSN 10/661,403

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

Claim 1 (withdrawn): An antiviral oligonucleotide formulation comprising at least one antiviral oligonucleotide, wherein the antiviral activity of said oligonucleotide occurs principally by a non-sequence complementary mode of action.

Claim 2 (withdrawn): An antiviral oligonucleotide formulation, comprising at least one antiviral randomer oligonucleotide, wherein the antiviral activity of said formulation occurs principally by a non-sequence complementary mode of action.

Claim 3 (withdrawn): An oligonucleotide formulation having antiviral activity against a target virus, comprising at least one antiviral oligonucleotide, wherein said oligonucleotide is at least 29 nucleotides in length and the sequence of said oligonucleotide is not complementary to any portion of the genomic sequence of said target virus.

Claim 4 (withdrawn): An oligonucleotide formulation having antiviral activity against a target virus, comprising at least one antiviral oligonucleotide, wherein said oligonucleotide is at least 6 nucleotides in length and the sequence of said oligonucleotide is not complementary to a mRNA of said target virus and does not consist essentially of polyA, polyC, polyG, polyT, Gquartet, or a TG rich sequence.

Claim 5 (withdrawn): The oligonucleotide formulation of any of claims 1 to 4, wherein said formulation has an IC<sub>50</sub> for a target virus of 0.05  $\mu$ M or less.

Claim 6 (withdrawn): The oligonucleotide formulation of any of claims 1 to 4, wherein said oligonucleotide targets a DNA virus.

Claim 7 (withdrawn): The oligonucleotide formulation of any of claims 1 to 4, wherein said oligonucleotide targets a RNA virus.

Claim 8 (withdrawn): The oligonucleotide formulation of any of claims 1 to 4, wherein said oligonucleotide is at least 29 nucleotides in length.

Commissioner of Patents  
USSN 10/661,403

Claim 9 (withdrawn): The oligonucleotide formulation of any of claims 1 to 4, wherein said oligonucleotide is at least 40 nucleotides in length.

Claim 10 (withdrawn): The oligonucleotide formulation of any of claims 1 to 4, wherein said oligonucleotide comprises at least one modification to its chemical structure.

Claim 11 (withdrawn): The oligonucleotide formulation of any of claims 1 to 4, wherein said oligonucleotide is a concatemer consisting of two or more oligonucleotide sequences joined by a linker.

Claim 12 (withdrawn): The oligonucleotide formulation of any of claims 1 to 4, wherein said oligonucleotide is linked or conjugated at one or more nucleotide residues, to a molecule modifying the characteristics of the oligonucleotide to obtain one or more characteristics selected from the group consisting of higher stability, lower serum interaction, higher cellular uptake, higher viral protein interaction, an improved ability to be formulated for delivery, a detectable signal, higher antiviral activity, better pharmacokinetic properties, specific tissue distribution, lower toxicity.

Claim 13 (withdrawn): The oligonucleotide formulation of any of claims 1 to 4, wherein said oligonucleotide is double stranded.

Claim 14 (withdrawn): The oligonucleotide formulation of any of claims 1 to 4, wherein said formulation further comprises a delivery system.

Claim 15 (withdrawn): The oligonucleotide formulation of any of claims 1 to 4, wherein said formulation further comprises a liposomal formulation.

Claim 16 (withdrawn): The oligonucleotide formulation of any of claims 1 to 4, wherein said oligonucleotide comprises at least one Gquartet motif portion.

Claim 17 (withdrawn): The oligonucleotide formulation of any of claims 1 to 4, wherein said oligonucleotide comprises at least one CpG motif portion.

Claim 18 (withdrawn): The oligonucleotide formulation of any of claims 1 to 4, wherein said oligonucleotide binds to one or more viral components.

Commissioner of Patents  
USSN 10/661,403

Claim 19 (withdrawn): The oligonucleotide formulation of any of claims 1 to 4, wherein at least a portion of the sequence of said oligonucleotide is derived from a viral genome.

Claim 20 (withdrawn): The oligonucleotide formulation of any of claims 1 and 4, comprising a mixture of at least two different antiviral oligonucleotides.

Claim 21 (withdrawn): An antiviral pharmaceutical composition comprising a therapeutically effective amount of at least one pharmacologically acceptable, antiviral oligonucleotide according to any of claims 1 to 4, wherein the antiviral activity of said oligonucleotide occurs principally by a non-sequence complementary mode of action; and a pharmaceutically acceptable carrier.

Claim 22 (withdrawn): The antiviral pharmaceutical composition of claim 21, adapted for delivery by a mode selected from the group consisting of intraocular injection, oral ingestion, enteral application, inhalation, topical application, subcutaneous injection, intramuscular injection, intraperitoneal injection, intrathecal injection, intratracheal injection, and intravenous injection.

Claim 23 (withdrawn): The antiviral pharmaceutical composition of claim 21, wherein said composition further comprises a delivery system.

Claim 24 (withdrawn): The antiviral pharmaceutical composition of claim 21, wherein said composition further comprises a liposomal formulation.

Claim 25 (withdrawn): A kit comprising at least one antiviral oligonucleotide or antiviral oligonucleotide formulation according to any of claims 1 to 4 in a labeled package, wherein the antiviral activity of said oligonucleotide occurs principally by a non-sequence complementary mode of action and the label on said package indicates that said antiviral oligonucleotide can be used against at least one virus.

Claim 26 (withdrawn): The kit of claim 25, wherein said kit is approved by a regulatory agency for use in humans.

Commissioner of Patents  
USSN 10/661,403

Claim 27 (withdrawn): A method for selecting an antiviral oligonucleotide for use as an antiviral agent, comprising synthesizing a plurality of different random oligonucleotides; testing said oligonucleotides for activity in inhibiting the ability of a virus to produce infectious virions; and selecting a said oligonucleotide having a pharmaceutically acceptable level of activity for use as an antiviral agent.

Claim 28 (currently amended): A method for the prophylaxis or treatment of a viral infection in a subject, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one pharmacologically acceptable oligonucleotide formulation comprising at least one antiviral oligonucleotide having an antiviral activity, wherein said antiviral oligonucleotide comprises at least one phosphorothioate linkage, wherein said antiviral activity of said oligonucleotide occurs principally by a sequence independent mode of action according to any of claims 1 to 4.

Claim 29 (original): The method of claim 28, wherein said subject is a human.

Claim 30 (withdrawn): A method for the prophylactic treatment of cancer caused by oncoviruses in a human or a non-human animal, comprising administering to a human or non-human animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least one oligonucleotide according to any of claims 1 to 4.

Claim 31 (withdrawn): The method of claim 30, wherein said oligonucleotide is administered to a human.

Claim 32 (withdrawn): A method of screening to identify a compound that alters binding of an oligonucleotide to at least one viral component, said method comprising in separate reactions, contacting said oligonucleotide with said viral component in the presence and absence of a compound to be screened; and determining whether a difference occurs in binding of said oligonucleotide to said viral component in the presence of said compound compared to in the absence of said compound, the presence of said difference being indicative of said compound altering the binding of said oligonucleotide to said viral component.

Commissioner of Patents  
USSN 10/661,403

Claim 33 (withdrawn): A novel antiviral compound identified by the method of claim 32.

Claim 34 (withdrawn): A method for purifying oligonucleotides binding to at least one viral component from a pool of oligonucleotides comprising: contacting said pool with at least one viral component; displacing bound oligonucleotides of said pool from said viral component; and collecting displaced oligonucleotides.

Claim 35 (withdrawn): The method of claim 34, further comprising sequencing, and testing antiviral activity of collected displaced oligonucleotides.

Claim 36 (withdrawn): A method for enriching oligonucleotides from a pool of oligonucleotides binding to at least one viral component, comprising: contacting said pool with at least one viral component ; and amplifying oligonucleotides bound to said viral component to provide an enriched oligonucleotide pool.

Claim 37 (withdrawn): The method of claim 36, wherein said contacting and amplifying are performed at least one additional time using said enriched oligonucleotide pool as the pool of oligonucleotides.

Claim 38 (withdrawn): The method of claim 36, further comprising sequencing and testing antiviral activity of oligonucleotides in said enriched oligonucleotide pool.

Claim 39 (withdrawn): An antiviral oligonucleotide preparation comprising one or more oligonucleotides identified using a method of any of claim 34 or 36, wherein said oligonucleotides in said oligonucleotide preparation exhibit higher mean binding affinity with at least one viral component than the mean binding affinity of oligonucleotides in the initial oligonucleotide pool.

Claim 40 (withdrawn): The antiviral oligonucleotide preparation of claim 39, wherein the mean binding affinity of said oligonucleotides is at least two-fold greater than the mean binding affinity of oligonucleotides in the initial oligonucleotide pool.

Claim 41 (new): A method for the prophylaxis or treatment of a viral infection in a subject, comprising administering to a subject in need of such treatment a therapeutically

Commissioner of Patents  
USSN 10/661,403

effective amount of at least one pharmacologically acceptable oligonucleotide formulation comprising at least one randomer oligonucleotide having an antiviral activity, wherein said randomer oligonucleotide comprises at least one phosphorothioate linkage, wherein the antiviral activity of said randomer oligonucleotide occurs principally by a sequence independent mode of action.

Claim 42 (new): A method for the prophylaxis or treatment of a viral infection in a subject, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one pharmacologically acceptable oligonucleotide formulation comprising at least one antiviral oligonucleotide having an antiviral activity, wherein said oligonucleotide is at least 29 nucleotides in length, comprises at least one phosphorothioate linkage, and the sequence of said oligonucleotide is not complementary to any portion of the genomic sequence of said target virus.

Claim 43 (new): A method for the prophylaxis or treatment of a viral infection in a subject, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one pharmacologically acceptable oligonucleotide formulation comprising at least one antiviral oligonucleotide targeting a virus and having an antiviral activity, wherein said antiviral oligonucleotide is at least 6 nucleotides in length, comprises at least one phosphorothioate linkage and the sequence of said oligonucleotide is free of complementarity to an mRNA of said target virus and is free of polyA, polyG, Gquartet or a TG-rich sequence, and wherein the antiviral activity of said oligonucleotide occurs principally by a sequence independent mode of action.